Citadel Advisors
FRTX

Citadel Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Citadel Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,054
Closed -$37K – 14491
2022
Q1 		$37K Sell
3,054
-692
-18% -$7.48K ﹤0.01% 12993
2021
Q4 		$39K Buy
3,746
+1,978
+112% +$35.5K ﹤0.01% 13387
2021
Q3 		$57K Sell
1,768
-18
-1% -$584 ﹤0.01% 13296
2021
Q2 		$76K Buy
+1,786
New +$73.4K ﹤0.01% 13111
2020
Q4 		– Sell
-293
Closed -$12K – 11690
2020
Q3 		$12K Buy
+293
New +$11.5K ﹤0.01% 9931
2019
Q3 		– Sell
-80
Closed -$21K – 9911
2019
Q2 		$21K Sell
80
-69
-46% -$23.1K ﹤0.01% 8943
2019
Q1 		$56K Buy
149
+63
+73% +$21.1K ﹤0.01% 8784
2018
Q4 		$32K Sell
86
-17
-17% -$6.67K ﹤0.01% 8604
2018
Q3 		$44K Buy
+103
New +$43.4K ﹤0.01% 8830
2018
Q2 		– Sell
-57
Closed -$26.8K – 9419
2018
Q1 		$26K Buy
+57
New +$28.3K ﹤0.01% 8085
2017
Q3 		– Sell
-78
Closed -$67K – 8192
2017
Q2 		$67K Buy
+78
New +$57K ﹤0.01% 7021
2016
Q3 		– Sell
-44
Closed -$63K – 7914
2016
Q2 		$63K Buy
44
+30
+214% +$38.6K ﹤0.01% 6350
2016
Q1 		$17K Buy
+14
New +$16.1K ﹤0.01% 6522
2015
Q3 		– Sell
-3
Closed -$6K – 9322
2015
Q2 		$6K Buy
+3
New +$9.41K ﹤0.01% 8520
2015
Q1 		– Sell
-5
Closed -$17K – 8937
2014
Q4 		$17K Buy
+5
New +$17.7K ﹤0.01% 7923
2014
Q3 		– Sell
-12
Closed -$45K – 8491
2014
Q2 		$45K Buy
12
+10
+500% +$37.6K ﹤0.01% 6828
2014
Q1 		$8K Sell
2
-8
-80% -$35.7K ﹤0.01% 7579
2013
Q4 		$39K Sell
10
-38
-79% -$144K ﹤0.01% 6169
2013
Q3 		$189K Buy
48
+46
+2,300% +$345K ﹤0.01% 4821
2013
Q2 		$22K Buy
+2
New +$22.2K ﹤0.01% 6033

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's FRTX Position: Q2 2022 in Review

Citadel Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2022, closing a stake of 3,054 shares — an estimated $37K sold.

Citadel Advisors first reported a position in FRTX in Q2 2013 and held it in 20 quarters. The position peaked at $189K in Q3 2013. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2022.

  • Citadel Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 3,054 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $37K.
  • Citadel Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 20 quarters.
  • Citadel Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $189K in Q3 2013.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.